Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
128.47
+2.66 (2.11%)
May 27, 2025, 3:05 PM - Market open
Biogen Stock Forecast
Stock Price Forecast
According to 22 professional analysts, the 12-month price target for Biogen stock ranges from a low of $115 to a high of $292. The average analyst price target of $194.95 forecasts a 51.75% increase in the stock price over the next year.
Price Target: $194.95 (+51.75%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Biogen stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 5 |
| Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Hold | 13 | 14 | 14 | 14 | 15 | 15 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 26 | 27 | 27 | 28 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $207 → $169 | Buy | Maintains | $207 → $169 | +31.55% | May 7, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $185 → $175 | Hold | Maintains | $185 → $175 | +36.22% | May 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $217 → $205 | Buy | Maintains | $217 → $205 | +59.57% | May 2, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $265 → $220 | Strong Buy | Maintains | $265 → $220 | +71.25% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $241 → $187 | Strong Buy | Maintains | $241 → $187 | +45.56% | May 2, 2025 |
Financial Forecast
Revenue This Year
9.45B
from 9.68B
Decreased by -2.31%
Revenue Next Year
9.28B
from 9.45B
Decreased by -1.84%
EPS This Year
15.29
from 11.18
Increased by 36.77%
EPS Next Year
15.78
from 15.29
Increased by 3.20%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.1B | 10.1B | 10.4B | ||
| Avg | 9.5B | 9.3B | 9.4B | ||
| Low | 8.8B | 8.2B | 8.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.2% | 6.7% | 11.8% | ||
| Avg | -2.3% | -1.8% | 1.1% | ||
| Low | -8.8% | -13.2% | -11.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.70 | 18.82 | 20.61 | ||
| Avg | 15.29 | 15.78 | 16.65 | ||
| Low | 14.27 | 12.48 | 12.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.3% | 23.0% | 30.6% | ||
| Avg | 36.8% | 3.2% | 5.5% | ||
| Low | 27.6% | -18.4% | -19.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.